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For 1 year, serogroup, serotype, serosubtype, and
penicillin susceptibility of meningococci circulating in vari-
ous regions in Portugal were evaluated. Most frequent phe-
notypes were B:4:P1.15 (13.4%) and C:2b:P1.2,5 (75.9%),
which are also common in Spain. Overall, 27.5% of
C:2b:P1.2,5 strains showed intermediate resistance to
penicillin. Laboratory-based surveillance of meningococcal
infection in Portugal provides important information to
assess the adequacy of public health measures.
I
n Europe, infections caused by Neisseria meningitidis
are associated with high rates of disease and death (1).
Outbreaks of invasive meningococcal disease, including
some cases of sudden death in some countries, suggest that
vaccination may be necessary to reduce the incidence of
this infection (2). Knowledge of the antigenic characteris-
tics of N. meningitidis would help determine the most
appropriate control strategies, which may vary from coun-
try to country.
Serogroups B and C are the most widespread, repre-
senting approximately 95% of cases of invasive meningo-
coccal disease in Europe (1), and serogroup B is the most
frequent cause of invasive meningococcal disease both in
America and Europe (3). Serotypes and serosubtypes can
be distinguished according to antigenic variants of the
outer membrane proteins PorB and PorA (4).
In Portugal, the Compulsory Notifiable Diseases sys-
tem is used, and meningococcal disease is a notifiable dis-
ease (5). The serogroup C conjugate vaccine was licensed
in 2000, and vaccination has been voluntary since the third
quarter of 2001. Laboratory analysis of serotypes and sero-
subtypes, not previously studied in meningococcal isolates
from Portugal, would contribute to understanding
meningococcal diversity and spread of meningococcal dis-
ease before the voluntary vaccination period.
We report a laboratory-based surveillance study of the
N. meningitidis serogroups, serotypes, and serosubtypes in
circulation in Portugal, as isolated from patients with cases
of cultured-confirmed invasive infection. Susceptibility to
penicillin was also evaluated.
The Study
A total of 116 isolates of N. meningitidis were detected
through a laboratory surveillance study; 27 hospitals from
different regions of Portugal participated. The investiga-
tion was conducted for 12 consecutive months (September
2000 to August 2001) after a 2-month pilot study (July and
August 2000) in six hospitals. The catchment population
of the participating hospitals included approximately
7,400,000 residents (71% of the Portuguese population).
Isolates of N. meningitidis were directly submitted at
–20ºC to the Antibiotic Resistance Unit in National
Institute of Health Dr. Ricardo Jorge, Lisbon, as pure iso-
lates. However, in some cases, only primary cultures per-
formed at participant hospitals were sent, at 35ºC, and
isolated in Antibiotic Resistance Unit. All strains were
identified by standard methods (6).
The inclusion criteria for laboratory diagnosis were as
follows: nonrepetitive and consecutive blood, cere-
brospinal fluid (CSF) samples, or both in persons with
symptoms compatible with invasive meningococcal dis-
ease. The strains from the pilot study were also included in
the analysis. Acase of invasive meningococcal disease was
defined as disease in which N. meningitidis had been
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Padre Américo, Vale de Sousa (A. Oliveira, F. Assunção); Hospital
Distrital de Aveiro, Aveiro (J. Roseta); Hospital Eduardo Santos
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Funchal, Funchal, Madeira (M. Freitas, T. Afonso).isolated by culture from two normally sterile sites (blood
and CSF) in a resident of the surveillance area. 
Serogroup was determined on 116 isolates by slide
agglutination with the polyclonal specific rabbit antisera
for A, C, X, Y, Z, W135, and 29E capsular polysaccharides
of N. meningitidis and the monoclonal antibodies to deter-
mine serogroup B (Murex Diagnostic, Dartford, U.K.) (6).
Serogroup findings by slide agglutination were checked by
polymerase chain reaction with previously described
primers (7).
For serotype and serosubtype analysis and susceptibili-
ty testing, 109 strains were available. Serotypes and sub-
types were determined by an enzyme-linked immunosor-
bent assay method (4) by using monoclonal antibodies
(RIVM, National Institute of Public Health and the
Environment, the Netherlands). Serotype-specific reagents
included 1, 4, 2a, 2b, 14, and 15; serosubtype-specific
reagents included P1.1, P1.2, P1.4, P1.5, P1.6, P1.7, P1.9,
P1.10, P1.12, P1.13, P1.14, P1.15, and P1.16. 
The susceptibility to penicillin (Wyeth Lederle
Portugal, Algés, Portugal) was assessed by determining
MICs by using the agar dilution method with Mueller-
Hinton agar supplemented with 5% sheep blood and incu-
bated in 5% CO2 at 35°C for 24 h. N. meningitidis strains
with an MIC of penicillin of <0.06 µg/mL were suscepti-
ble, strains with an MIC of penicillin of 0.12 µg/mL to
1  µg/mL had intermediate resistance to penicillin.
Escherichia coli ATCC 25922 and Staphylococcus aureus
ATCC 29213 were used as control strains. Production of β-
lactamase was tested by nitrocefin (a chromogenic
cephalosporin method).
The study sample included slightly more serogroup C
(58/116, 50.0%) than serogroup B (55/116, 47.4%) iso-
lates; the rest were serogroup W135 (3/116, 2.6%). The
most frequent type and subtype of serogroup B was
4:P1.15 (13.4%) and of serogroup C was 2b:P1.2,5
(75.9%) (Table). Phenotype C:2b:P1.2,5 accounted for
37.6% of all strains, but no differences existed by age and
region (data not shown). Most of the 41 strains with this
phenotype were isolated from November 2000 through
June 2001, with a peak from February 2001 to April 2001
(Figure). This peak contributed to the higher number of
isolates obtained during this period.
Strains with intermediate resistance to penicillin from
serogroup B had the following serotypes and subtypes:
4:P1.15 (two strains) and one strain of each 1:P1.15,
4:P1.2,5, 14:P1.12 and NT:P1.15. Strains with intermedi-
ate resistance to penicillin from serogroup C had the fol-
lowing serotypes and subtypes: 2b:P1.2,5 (30 strains) and
2b:P1.2 (2 strains) and 2b:NST (2 strains). One strain from
the phenotype W135:2a:P1.2,5 also showed intermediate
resistance to penicillin (Table).
Conclusions
This study, covering approximately 71% of the
Portuguese population, shows that serogroups B and C are
dominant in Portugal, as they are elsewhere in Europe (1).
Meningococcal disease in our study followed the usual
European pattern (1), including the seasonal peak in win-
ter and the age distribution, with children <5 years of age
being the most affected group (data not shown). 
B:15:P1.7,16 and B:4:P1.4 were the fourth and fifth
most frequent serotype and subtypes of serogroup B in our
sample, respectively, but were the major phenotypes of
invasive meningococci in other European countries in
1999 and 2000, followed by B:4:P1.15, B:1:P1.14 and
B:4:P1:10, in descending order (1,9). However, the most
frequent serotype and subtype of serogroup B in this study
was 4:P1.15 (13.4%), as in Spain (1). Spain was the only
European country to report phenotype B:4:P1.15 from
1993 to 1996 (9), but it was found in the Czech Republic,
Slovakia, and Malta in 1999 through 2000 (1). 
Between serogroup C strains, those with serotype and
subtype 2b:P1.2,5 (75.9%) were the most frequent, fol-
lowed by 2b:P1.2 (7.5%) (1,9). In Europe, in 1999 through
2000, the prevalent phenotypes for strains of serogroup C
were C:2a:P1.5 and C:2a:P1.2,5, followed by C:2b:P1.2,5,
C:2b:P1.2, and C:2a:P1.2 (1).
The apparent endemicity of N. meningitidis
C:2b:P1.2,5 in Portugal (Figure) (8), as in Spain, suggests
that the features of the Iberian Peninsula are favorable for
this phenotype. Invasive meningococcal disease may be
caused by host factors more than bacterial determinants
(10,11). Molecular analysis may be able to indicate
whether the phenotype 2b:P1.2,5 is a variant of clones
spreading in other countries or even a variant of previous-
ly identified clones in Portugal. Monitoring the incidence
of this phenotype and its apparent emergence from 1995
(33.3%) to 2001 (75.9%) (Table) (8) is important.
The three strains of serogroup W135 in this study were
all serotype and subtype 2a:P1.2,5, the predominant clone
in Europe (1). This serotype was the cause of an outbreak
in 2000, after the Hajj pilgrimage to Mecca (12). We have
no information about contact between patients and Hajj
pilgrims or the European outbreak. However, the main
serotype and subtype in serogroup W135 in Portugal pre-
viously (between 1995 and 1999) was also 2a:P1.2,5
(Table).
The emergence of serogroup C, including numerous
isolates with intermediate resistance to penicillin (13,14),
leads us to emphasize the importance of the prophylaxis
and the need for cost-benefit studies to control meningo-
coccal disease. Resistance to penicillin can impede treat-
ment of invasive disease, making surveillance of this
resistance important. Strains of phenotypes B:4:P1.15 and
C:2b:P1.2,5 most frequently had intermediate resistance to
Neisseria meningitidis C:2b:P1.2,5
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penicillin (all isolates with MIC of 0.5 µg/mL and 95%
with MIC of 0.25 µg/mL). In Spain in the 1980s, types
4:P1.15 (serogroup B) and 2b (serogroup C) were also
found in the main meningococci with intermediate resist-
ance to penicillin (14).
In conclusion, continued serogrouping of meningococ-
cal strains would be valuable because possible antigen
variations caused by capsular switching (15) can occur
after the period of this study, especially because of the vol-
untary vaccination program available in Portugal.
Meningococci use this mechanism to escape control by
vaccines or the natural immune protection. Consequently,
the pattern of phenotypes could be subject to major
changes, and adjustment to new circumstances will be
needed. Antigenic characterization has contributed to the
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Table. Distribution of 109 invasive meningococcal isolates by serogroup, serotype, serosubtype and susceptibility to penicillin 
Penicillin susceptibility
 
Serogroup  
(no. of strains) 
Serotype 
 (no. of strains)  Serotype: subtype
a  No. of strains (%)  MIC (µg/mL)  S, IR
b 
No. of strains with the same 
phenotype in 1995–1999
b,c 
1:NST  6 (11.6)  0.06  S   
1:P1.13  2 (3.8)  0.06  S   
1:P1.14  1 (1.9)  0.06  S   
1:P1.15  1 (1.9)  0.25  IR   
1:P1.4  1 (1.9)  0.06  S   
1 (n = 12) 
1:P1.9  1 (1.9)  0.06  S   
2b (n = 1)  2b:NST  1 (1.9)  0.06  S   
4:P1.2,5  2 (3.8)  0.06  S   
  1 (1.9)  0.125  IR   
4:P1.4
  3 (5.8)  0.06  S   
4:P1.6  1 (1.9)  0.06  S   
4:P1.14  1 (1.9)  0.06  S  1 (IR) 
4:P1.15  5 (9.6)  0.06  S  1 (S) 
  2 (3.8)  0.125  IR   
4 (n = 16) 
4:NST  1 (1.9)  0.06  S   
14:NST  1 (1.9)  0.06  S  3 (S)  14 (n = 2) 
14:P1.12  1 (1.9)  0.25  IR   
15:P1.7  1 (1.9)  0.06  S    15 (n = 6) 
15:P1.7,16  5 (9.6)  0.06  S  5 (S) 
NT:P1.2,5  1 (1.9)  0.06  S   
NT:P1.6  1 (1.9)  0.06  S  2 (S) 
NT:P1.7,16  1 (1.9)  0.06  S  1 (IR) 
NT:P1.9  5 (9.6)  0.06  S  1 (S) 
NT:P1.12  1 (1.9)  0.06  S   
2 (3.8)  0.06  S  1 (S)  NT:P1.15 
1 (1.9)  0.25  IR   
B (n = 52) 
NT (n = 15) 
NT:NST  3 (5.8)  0.06  S  1 (IR) 
2a:P1.2,5  1 (1.9)  0.06  S  2 (S)  2a (n = 2) 
2a:P1.5  1 (1.9)  0.06  S   
2 (3.7)  0.06  S  1 (IR) 
1 (1.9)  0.125  IR   
2b:P1.2 
1 (1.9)  0.25  IR   
11 (20.4)  0.06  S  18 (3 S, 15 IR) 
10 (18.5)  0.125  IR   
18 (33.3)  0.25  IR   
2b:P1.2,5 
2 (3.7)  0.5  IR   
2b:P1.5  1 (1.9)  0.06  S  1 (IR) 
1 (1.9) 
2b (n = 48) 
2b:NST 
1 (1.9) 
0.25 
0.5 
IR 
IR 
1 (IR) 
15 (n = 1)  15:NST  1 (1.9)  0.06  S   
NT:P1.2,5  1 (1.9)  0.06  S   
NT:P1.5  1 (1.9)  0.06  S   
C (n = 54) 
NT (n = 3) 
NT:NST  1 (1.9)  0.06  S   
2 (66.7)  0.06  S  4 (3S, 1IR)  W135 (n = 3)  2a (n = 3)  2a:P1.2,5 
1 (33.3)  0.125  IR   
aNT, non-serotypeable; NST, non-serosubtypeable.
 
bS, susceptible; IR, intermediate resistance. 
cPhenotypes that already existed in a strain collection isolated in nine Portuguese hospitals from January 1995 to December 1999 (n = 54) (8). Phenotypes present in the 
earlier collection not found in our study (unpub. data) are: B:2b:P1.5, B:4:P1.7, B:15:P1.9, B:15:P1.13, B:15:NST, B:NT:P1.14, B:NT:P1.16, C:2a:P1.14, C:2a:NST, 
C:4:P1.12; W135:NT:NST (n = 1 for each phenotype). understanding of meningococcal diversity and spread of
meningococcal disease. Trends were detected epidemio-
logically, and serotyping provided further information,
which can also contribute to establishing strategies for
developing a universal serogroup B vaccine. Molecular
typing of N. meningitidis is also needed in Portugal to fol-
low evolutionary changes in the bacteria and to elucidate
clonal relationships between isolates.
Our results also demonstrate the importance of moni-
toring susceptibility to antimicrobial drugs and antigenic
characteristics of meningococci; in Portugal, the prevalent
phenotype C:2b:P1.2,5 is of particular concern.
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Figure. Distribution of Neisseria meningitidis collected in Portugal
from July 2000 to August 2001 and phenotype C:2b:P1.2,5.
Search past issues of EID at www.cdc.gov/eid
The opinions expressed by authors contributing to this journal do
not necessarily reflect the opinions of the Centers for Disease
Control and Prevention or the institutions with which the authors
are affiliated.